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Abstract
Zinc transporter 8 (ZnT8), a protein highly specific to pancreatic insulin-producing beta cells, is vital for the biosynthesis and
secretion of insulin. ZnT8 autoantibodies (ZnT8A) are among the most recently discovered and least-characterised islet autoan-
tibodies. In combination with autoantibodies to several other islet antigens, including insulin, ZnT8A help predict risk of future
type 1 diabetes. Often, ZnT8A appear later in the pathogenic process leading to type 1 diabetes, suggesting that the antigen is
recognised as part of the spreading, rather than the initial, autoimmune response. The development of autoantibodies to different
forms of ZnT8 depends on the genotype of an individual for a polymorphic ZnT8 residue. This genetic variant is associated with
susceptibility to type 2 but not type 1 diabetes. Levels of ZnT8A often fall rapidly after diagnosis while other islet autoantibodies
can persist for many years. In this review, we consider the contribution made by ZnT8 to our understanding of type 1 diabetes
over the past decade and what remains to be investigated in future research.
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Abbreviations
GADA GAD65 autoantibodies
IAA Insulin autoantibodies
IA-2A Islet antigen-2 autoantibodies
LIPS Luciferase immunoprecipitation system
ZnT8 Zinc transporter 8
ZnT8A ZnT8 autoantibodies
ZnT8RA ZnT8 arginine-specific autoantibodies
ZnT8WA ZnT8 tryptophan-specific autoantibodies
Introduction
Islet autoantibodies develop before the clinical onset of type 1
diabetes and are currently the principal biomarkers for
identifying individuals at risk of the disease. Detection of
multiple autoantibody positivity in childhood implies an
80% risk of developing diabetes within 15 years, although
the rate of progressions varies from a few months to decades
[1]. In 2007, zinc transporter 8 (ZnT8) autoantibodies
(ZnT8A) were characterised [2] and have since been
recognised [1, 3] as one of the four major islet autoantibodies,
together with GAD65 autoantibodies (GADA) [4], islet
antigen-2 autoantibodies (IA-2A) [5] and insulin autoanti-
bodies (IAA) [6].
ZnT8 is encoded by SLC30A8 and the first genome-wide
association study (GWAS) linking a polymorphism in this
gene, on chromosome 8q24.11, with type 2 diabetes was pub-
lished in 2007 [7]. The common single nucleotide polymor-
phism (SNP) in SLC30A8, rs13266634 (C/T), causes a non-
synonymous R325Wmodification in the protein sequence [7,
8]. The SLC30A8 genotype appears to impact insulin produc-
tion [9] and rare protective loss-of-function mutations in this
gene can increase insulin secretory capacity and reduce type 2
diabetes risk considerably [10, 11]. Numerous studies and a
meta-analysis have shown that the rs13266634 SNP is not
associated with overall type 1 diabetes risk in childhood
[12]. However, data from the German prospective cohort stud-
ies BABYDIAB and BABYDIET suggested that SLC30A8
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may influence age at onset of diabetes and rate of progression
within predisposed individuals, perhaps by its effect on insulin
production [13, 14]. In this review, we consider questions
concerning the autoimmune response to ZnT8 in type 1 dia-
betes that remain to be answered (summarised in Table 1).
The structure and function of ZnT8
A member of the zinc transporter family, ZnT8 is highly
expressed in the pancreatic beta cells, where it is the most abun-
dantly expressed zinc transporter [15]. Like other major
autoantigens in type 1 diabetes, ZnT8 has high beta cell spec-
ificity and is localised to insulin secretory granules (Fig. 1a).
ZnT8 is important for beta cell function, through its role in
supplying zinc ions (Zn2+) for insulin storage and biosynthesis
[16]. ZnT8 is a 369-amino acid polytopic transmembrane pro-
tein with cytoplasmic N- and C- terminal tails (Fig. 1b) [11, 17].
The development of the ZnT8A immune
response
The structure of ZnT8 suggests that less than half of the pro-
tein is accessible to immune surveillance and this may explain
why ZnT8 is a target of autoimmune attack in type 1 diabetes.
The whole protein or fragmented peptides are most likely to
be accessible to the immune system upon beta cell death,
although following granule exocytosis, during insulin secre-
tion, the luminal transmembrane domains are exposed extra-
cellularly [18].
Initiation of ZnT8 autoimmunity At diagnosis, IAA, IA-2A
and GADA are associated with specific HLA class II alleles
contained within type 1 diabetes risk genotypes [19, 20]. In
contrast, ZnT8A have not shown consistent HLA class II as-
sociations [21], except with DQ6.4 in individuals with type 1
diabetes [22]. They are, however, associated with high diabe-
tes risk (i.e. DR3/DR4) in first-degree relatives. Epitope scan-
ning identified more putative ZnT8 epitopes for HLA-DQ2
than for -DQ8 or -DQ6.4 [23]. An intermediate binding epi-
tope for HLA-DQ2was predicted to bindW325 but not R325,
suggesting that this may contribute to differences in central
tolerance for ZnT8. However, regardless of DQ type, people
with diabetes had a higher frequency of proinflammatory
ZnT8-specific CD4+ T cells than age- and HLA-matched
non-diabetic individuals [24].
The predisposing HLA class I A*24 allele was negatively
associated with presence of ZnT8A at and before diagnosis
when age at onset was accounted for [25, 26]. Studies of ZnT8
epitopes for CD8+ T cells have focused on the better-
characterised HLA-A*2. There is evidence that CD8+ T cells
recognise a range of ZnT8 peptides across the transmembrane/
loop and C-terminal regions in individuals with diabetes
[27–29]. This could suggest previous epitope spreading but
may also reflect the technical challenge of detecting and
characterising antigen-specific T cell responses ex vivo. The
number and phenotype of ZnT8-specific T cells identified in
people with and without diabetes appear to be similar but
functional differences have been identified, such as greater
ZnT8-stimulated IFN-γ secretion by isolated CD8+ T cells
from people with diabetes [30]. In the pancreases of people
who had type 1 diabetes, compared with type 2 diabetes or no
diabetes, more ZnT8-specific CD8+ T cells were present, sug-
gesting that ZnT8-specific lymphocytes home to the pancreas.
Table 1 A summary of important unanswered questions about the immune response to ZnT8 in type 1 diabetes
Stage Field of study
Genetics B cell responses T cell responses
Initiation of
autoimmunity
How do HLA genotypes alter central tolerance
for ZnT8?
Is the C-terminal always the target of
ZnT8A?
What causes ZnT8 to become a
target of autoimmunity?
Before
diabetes
Do SNPs in SLC30A8 influence the rate of
progression in people at risk of type 1
diabetes?
Does epitope spreading occur across
ZnT8?
Are ZnT8A preferentially lost in rapid
progressors or do they appear less
often?
The broad T cell response to ZnT8
suggests previous epitope
spreading; when does this occur?
At diagnosis Do common SNPs modulate age of onset and
what is the mechanism of this?
What is the frequency of ZnT8A in
adult-onset T1D?
How can it help us distinguish subtypes of
diabetes?
How does HLA-A*24 present ZnT8
peptide compared with HLA-A*2?
During
diabetes
Does the SLC30A8 genotype predict long-term
clinical outcomes following diagnosis?
Why are ZnT8A lost more rapidly
compared with GADA or IA-2A?
Does this correlate with beta cell function?
Why are ZnT8 Tcell responses lost over
the first few years after diagnosis?
Is this because of rapid loss of antigen?
T1D, type 1 diabetes
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ZnT8 as an autoantigenHumoral islet autoimmunity can devel-
op in children as young as 6months of agewith a peak incidence
of seroconversion at 2–3 years and a probable second peak in
puberty [1]. The first autoantibodies to develop in young
children are typically IAA and/or GADA and, therefore, insulin
and GAD65 are often regarded as primary targets of autoimmu-
nity. In contrast, IA-2A and ZnT8A are rarely the only islet
autoantibodies identified at primary seroconversion; data for
ZnT8A are, however, more limited [2, 14]. Although ZnT8A
can be detected close to initiation of autoimmunity, ZnT8A
and IA-2A typically arise later in prediabetes and are more com-
mon in adolescents at diagnosis. Similarly, in mice, transfer of
ZnT8 C-terminal-specific CD4+ T cells only caused diabetes if
insulitis was present. Additionally, ZnT8-specific CD4+ T cells
were only found in pancreas and lymph nodes of mice in ad-
vanced disease [31], supporting the observation that antigen
spreading to ZnT8 is characteristic of the developing autoim-
mune response.
Most of the mature ZnT8A responses recognise the C-
terminal of the protein and only 10% recognise the N-terminal
[3]. Within the C-terminal, ZnT8A can be specific to amino acid
325 of ZnT8 (Fig. 1c) and this specificity is defined by the
SLC30A8 polymorphism rs13266634 [32]. Hence, individuals
with the CC genotype (R325) rarely develop ZnT8 tryptophan-
specific autoantibodies (ZnT8WA) and individuals with the TT
genotype (W325) rarely develop ZnT8 arginine-specific autoan-
tibodies (ZnT8RA). Competitive displacement experiments
show that ZnT8A are truly specific for R325 or W325 [33].
Thus, individuals respond to endogenous ZnT8 protein deter-
mined by their own genome. This has not been as easy to dem-
onstrate for the other islet antigens because they lack an amino
acid polymorphism with such an obvious influence on the auto-
antibody response. In several populations, ZnT8A appear to
cross-react with a viral protein from Mycobacterium avium
subsp. paratuberculosis (e.g. [34]) and around 50% of ZnT8A-
positive individuals have antibodies recognising epitopes inde-
pendent of amino acid 325 [32]. Therefore, molecular mimicry
could be a contributing factor in the initial response to ZnT8 but
more work is needed to evaluate this.
For other islet autoantibodies, epitope spreading has been
demonstrated to occur during progression, and identification of
epitopes indicative of later stages of disease has improved the
specificity of these markers [35, 36]. Investigations into ZnT8
epitope autoantibody responses have focused on samples taken
close to disease onset. In addition to thewell-characterised amino
acid 325R/W polymorphism, a second SNP, rs16889462 (G/A)
which encodes Q325, has also been identified but is present in
<1% of Europeans. A conformational ZnT8A epitope (depen-
dent on R332, E333, K336 and K340 but independent of R325)
[37] was characterised by comparing human andmouse chimeric
ZnT8 proteins. The importance of conformational epitopes to
ZnT8A responses is also supported by the observation that linear
15 amino acid ZnT8 peptides were insufficient to displace
ZnT8A [38]. If epitopes of ZnT8A associated with higher risk
of diabetes could be identified, these would aid prediction but the
pattern of epitope-specific responses before diagnosis has not so
far proved useful for risk stratification.
a
b
c
Fig. 1 (a) Schematic diagram of the pancreatic islet beta cell illustrating
the locations of the major antigens that autoantibodies recognise:
GAD65, islet antigen-2 (IA-2), insulin and the zinc transporter ZnT8.
IA-2, insulin and ZnT8 are found within insulin secretory granules but
GAD65 is found within synaptic-like microvesicles within the beta cell.
(b) The structure of the transmembrane protein ZnT8, which is embedded
within insulin secretory granule membranes. The C- and N-terminals are
cytosolic but the transmembrane domains (numbered 1–6) include three
luminal regions, which are expressed extracellularly during insulin gran-
ule exocytosis. Adapted from [2]. Copyright 2007 National Academy of
Sciences. (c) The codons for the major allele and the SNPs in SLC30A8,
which encodes ZnT8. These SNPs determine protein sequence at amino
acid (aa)325 in the C-terminal of ZnT8. Themajor allele (encoding R325)
is associated with increased risk of type 2 diabetes; however, in type 1
diabetes, this SNP influences autoantibody specificity to ZnT8 and can
aid risk stratification of disease progression.MAF,minor allele frequency.
This figure is available as part of a downloadable slideset
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Predicting diabetes using ZnT8A
Wenzlau et al first described ZnT8A in 2007; analysis of 43
individuals at high genetic risk followed prospectively showed
that ZnT8A could stratify risk in those positive for IAA, GADA
or IA-2A alone [2]. Subsequently, the prospective birth-cohort
study BABYDIAB also showed that ZnT8A aid prediction of
disease in the presence or absence of other islet autoantibodies
[14]. Themuch larger TrialNet dataset confirmed these findings
and concluded that screening for ZnT8A should be included in
prediction and prevention studies [39]. Several studies have
shown that combined testing for IA-2A and ZnT8A identifies
relatives who progress rapidly to disease in the most cost-
effective way [40–42]. The contribution of ZnT8A in predicting
risk is likely age-dependent; as the benefit of adding ZnT8A in
single-islet-autoantibody-positive individuals in the Diabetes
Autoimmunity Study in the Young (DAISY) was found when
onset was after age 6 years [2]. In preselected relatives who
were positive for other islet autoantibodies, ZnT8A only added
to risk prediction in relatives who were older or who were at
genetically lower risk [43]. Within those who progress slowly
to disease, ZnT8A are frequently detected [44]. Most studies of
risk stratification for type 1 diabetes have been conducted in
relatives or individuals with high HLA class II risk. The added
predictive value of ZnT8A in the general population has not
been fully assessed but is ongoing (e.g. in the German Fr1da
study [45]). Despite contradictions, current evidence suggests
that screening for ZnT8A will provide additional information
about risk, especially in older individuals in whom early auto-
immune responses to insulin are waning.
Lessons learnt from ZnT8A measured
at diagnosis
When ZnT8A were originally characterised, these autoanti-
bodies increased the number of people identified as single-
or multiple-antibody positive at diabetes onset. Of 133 indi-
viduals negative for IAA, GADA and IA-2A at diagnosis,
26% were positive for ZnT8A and 47% of 51 people positive
for a single antibody (IAA, GADA or IA-2A) became
multiple-antibody positive when ZnT8A were considered
[2]. Overall, several international studies have shown that
around two-thirds of children are ZnT8A positive at diagnosis
[32, 46]; depending on the age group considered, the preva-
lence is similar to IA-2A.
The importance of ZnT8A as a biomarker in adult disease
has not been fully assessed. One study from Belgium sug-
gested that only half of those diagnosed over the age of
20 years are positive for ZnT8A [40]. This frequency is less
than for GADA (65%) but comparable with IA-2A (45%) [47,
48]. The contribution of ZnT8A in populations defined as
LADA is difficult to determine because the characteristics of
the participants vary between studies. There is, however, evi-
dence that screening for ZnT8A reduces the cost of discrimi-
nating monogenic diabetes [49].
ZnT8A also contributed to our observation that the natural
history of humoral autoimmunity may be changing. In our
UK-based study, carried out between 1985 and 2002 in indi-
viduals at disease onset, the prevalence of IA-2A and ZnT8A
increased while that of GADA and IAA remained stable over
time [46]. This could indicate a shift towards a more aggres-
sive form of disease, as IA-2A and ZnT8A tend to develop
later in pathogenesis. During the same time period, the inci-
dence of diabetes in younger children has increased and the
proportion of probands with high genetic risk has reduced,
suggesting an increase in environmental risk [50, 51]. Lower
genetic risk alleles, such as DQ6.4, could therefore have
become more common in people with diabetes and contribut-
ed to increased ZnT8A. A Danish study, covering a shorter
time span, found no difference in prevalence of IA-2A or
GADA in individuals at the time of diagnosis (1997–2005)
but ZnT8Awere not measured [52].
ZnT8A as a biomarker of insulin secretory
capacity post diagnosis
Another suggestion from the initial 2007 paper was that
ZnT8Amay be correlatedwith loss of insulin secretion because
of ZnT8’s beta cell specificity and co-localisation with insulin
[2]. Following initially successful pancreas transplant, ZnT8A
have been associated with rapid onset of hyperglycaemia and
eventual loss of graft function, making them a potentially im-
portant biomarker for predicting beta cell loss [53]. Ongoing
beta cell death is likely to drive levels of ZnT8A [2, 54], al-
though low-level expression in non-functional beta cells or
neighbouring alpha cells may also contribute. After diagnosis
ZnT8A are lost more rapidly than GADA or IA-2A [2], while
Tcell responses, particularly to the transmembrane domain, are
also lost within a few years post diagnosis [28]. This is impor-
tant because if ZnT8A, which are easier to measure than T
cells, reflect insulin secretory capacity and autoreactivity, they
may be useful biomarkers for assessing/monitoring the efficacy
of clinical trials. In 2013, Ingemansson et al showed that in a
group of 15–34 year olds with diabetes (71% type 1), high C-
peptide (indicative of endogenous insulin secretion) at diagno-
sis correlated with prospective preservation of ZnT8A 5 years
after diagnosis [55]. However, another study in individuals
with younger onset showed that high positivity for ZnT8A at
diagnosis was associated with lower C-peptide levels and in-
creased insulin dose within the first 2 years after diagnosis,
despite similar levels at disease onset [56]. In a minority of
individuals where ZnT8A persist for decades after diagnosis,
cross-sectional studies have also failed to reach a consensus
about the relationship between ZnT8A and C-peptide
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[57–59]. These contrasting findings could be explained if age
at diagnosis influences this association. The hypothesis that
ZnT8A could be used as a biomarker for therapeutic effect is
attractive but is not strongly supported by current literature.
What benefits could new assays for ZnT8A
offer for prediction?
Currently, the gold standard method for measuring circulating
islet autoantibodies, including ZnT8A, is RIA. Internationally,
RIAs for GADA and IA-2A have been harmonised but work
to standardise measurement of ZnT8A and IAA is ongoing
[60]. These assays have proved highly specific and sensitive
in differentiating healthy individuals from diabetic individuals
and have been used to investigate C-terminal epitopes
recognised by ZnT8A [2, 32]. However, this method is disad-
vantaged by the use of costly radioisotopes, which are tightly
regulated and have limited shelf lives. The main assay devel-
opment has been to create dimers (Fig. 2a) of the amino acid
268–369 sequence connected by a linking sequence to allow
for the simultaneous measurement of antibodies to the most
common R325 andW325 variants using RIA (Fig. 2b). In one
Finnish study, addition of a Q325 probe further increased RIA
sensitivity by reducing the number of antibody-negative chil-
dren and adolescents [61].
Alternative assays, such as the luciferase immunoprecipi-
tation system (LIPS) (Fig. 2c) and ELISAs (Fig. 2d), have
begun matching or even exceeding the specificity and sensi-
tivity of RIAs for GADA and IA-2A [62, 63]. While ELISAs
eliminate the requirement for radioisotopes, sample volume
requirements greatly exceed those of RIAs (increased from
4 μl per test to 50 μl); LIPS assays offer similar performance
to RIAs with potentially even lower sample volume require-
ments [64]. This would facilitate the use of small volume
samples such as capillary bleeds for screening young infants
and the general population.
There are assays in development that may maintain the
conformational structure of ZnT8. In 2017 Wan et al devel-
oped a novel assay using full-length ZnT8 (R325) in
a
b
d
e
c
Fig. 2 (a) Dimeric C-terminal probes enable measurement of ZnT8RA
and ZnT8WA in a single assay [65]. Monomeric probes can also be used.
(b–e) Multiple assay formats have been employed tomeasure ZnT8A. (b)
The gold standard RIA, C-terminal ZnT8A assay, uses 35S-methionine
and Protein A Sepharose (PAS) to immunoprecipitate ZnT8A in serum.
(c) LIPS employs antigen-conjugated N-luciferase (N-Luc) and the
substrate furimazine to produce a detectable luminescence signal. LIPS
has a similar assay format to gold standard RIAs and provides an
alternative to radioisotope use. (d) The routinely used commercial ZnT8
bridge ELISA (developed by RSR) employs plates coated in C-terminal
ZnT8 and detects ZnT8A by means of a biotin–streptavidin–peroxidase
system, where the peroxidase acts as a substrate to 3,3′, 5,5′-
tetramethylbenzidine (TMB) to create a colourogenic reaction
proportionate to the level of ZnT8A [66]. (e) A method for measuring
ZnT8A responses outside of the C-terminal, through a three-dimensional
format, has been proposed, creating scope for elucidating conformational
epitopes. This method uses full-length ZnT8 and proteoliposomes
immobilised on pGOLD platform plates. Detection of ZnT8A is
through binding of anti-human IgG Fc secondary antibodies conjugated
to a fluorophore. (e) Adapted from [54]. a indicates that the exact ZnT8
sequences for these assays are still being optimised (c) or are proprietary
(d). aa, amino acid. This figure is available as part of a downloadable
slideset
b
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combination with proteoliposomes (Fig. 2e) [54]. This assay
has the potential to detect ZnT8A that recognise epitopes
outside the C-terminal but the need to use the pGOLD plat-
form restricts routine application of this assay due to costs.
Future assay adaptations to investigate other epitopes, includ-
ing post-translational protein modification, and that are vali-
dated on ‘at-risk’ individuals before disease onset may im-
prove disease prediction and should continue to be
investigated.
Conclusion
Measurement of ZnT8A is a cost-effective method by which
to identify multiple-islet-autoantibody-positive individuals at
increased risk of diabetes. This marker may be particularly
useful in assigning risk from adolescence onwards. The study
of ZnT8A has also given us vital evidence of a true autoim-
mune response and strengthens observations that the patho-
genesis of the disease may change over generations. In the
future, the influence of variants in SLC30A8 on the rate of
progression to clinical type 1 diabetes should be clarified,
especially in those with age of onset above 15 years. Why
autoimmunity spreads to target ZnT8 later in the pathogenesis
of the disease, why this response is lost rapidly after diagnosis
and whether these changes are related to beta cell function are
just some of the questions that still require clarification.
Analysis of ZnT8A and T cell epitopes before diagnosis will
improve our understanding of disease pathogenesis and pro-
vide better biomarkers of disease.
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